Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VictORION-INCLUSION
NCT06249165Phase 4Active, not recruiting
- Sponsor
- Duke University
- Start
- Dec 2024
- Primary completion
- Dec 2026
- Modality
- Antisense DNA, Conjugated siRNA, MicroRNA (miRNA)
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of inclisiran in atherosclerotic cardiovascular disease (ASCVD) and hypercholesterolemia (2 arms), sponsored by Duke University. Primary endpoint: Achievement of LDL-C targets at 360 days. Started Dec 2024; status: active, not recruiting.
02
Drugs
inclisiran
03
Conditions
atherosclerotic cardiovascular disease (ASCVD)hypercholesterolemia
Beyond the preview
Go deeper on NCT06249165.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06249165.